vs

Side-by-side financial comparison of Cytosorbents Corp (CTSO) and NexPoint Real Estate Finance, Inc. (NREF). Click either name above to swap in a different company.

NexPoint Real Estate Finance, Inc. is the larger business by last-quarter revenue ($11.1M vs $9.2M, roughly 1.2× Cytosorbents Corp). NexPoint Real Estate Finance, Inc. runs the higher net margin — 216.6% vs -59.5%, a 276.2% gap on every dollar of revenue. On growth, Cytosorbents Corp posted the faster year-over-year revenue change (0.9% vs -48.8%).

CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.

NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.

CTSO vs NREF — Head-to-Head

Bigger by revenue
NREF
NREF
1.2× larger
NREF
$11.1M
$9.2M
CTSO
Growing faster (revenue YoY)
CTSO
CTSO
+49.7% gap
CTSO
0.9%
-48.8%
NREF
Higher net margin
NREF
NREF
276.2% more per $
NREF
216.6%
-59.5%
CTSO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CTSO
CTSO
NREF
NREF
Revenue
$9.2M
$11.1M
Net Profit
$-5.5M
$24.0M
Gross Margin
73.7%
Operating Margin
-47.5%
Net Margin
-59.5%
216.6%
Revenue YoY
0.9%
-48.8%
Net Profit YoY
27.4%
58.7%
EPS (diluted)
$-0.09
$0.47

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTSO
CTSO
NREF
NREF
Q4 25
$9.2M
$11.1M
Q3 25
$9.5M
$12.5M
Q2 25
$9.6M
$12.1M
Q1 25
$8.7M
$11.5M
Q4 24
$9.2M
$21.7M
Q3 24
$8.6M
$12.5M
Q2 24
$8.8M
$6.7M
Q1 24
$9.0M
$-12.8M
Net Profit
CTSO
CTSO
NREF
NREF
Q4 25
$-5.5M
$24.0M
Q3 25
$-3.2M
$50.9M
Q2 25
$1.9M
$22.3M
Q1 25
$-1.5M
$26.0M
Q4 24
$-7.6M
$15.2M
Q3 24
$-2.8M
$23.3M
Q2 24
$-4.3M
$12.1M
Q1 24
$-6.1M
$-14.6M
Gross Margin
CTSO
CTSO
NREF
NREF
Q4 25
73.7%
Q3 25
70.3%
Q2 25
70.9%
Q1 25
71.1%
Q4 24
68.4%
Q3 24
61.0%
Q2 24
73.5%
Q1 24
76.5%
Operating Margin
CTSO
CTSO
NREF
NREF
Q4 25
-47.5%
Q3 25
-30.2%
Q2 25
-37.6%
Q1 25
-44.5%
Q4 24
-37.1%
Q3 24
-56.1%
Q2 24
-40.4%
Q1 24
-51.8%
Net Margin
CTSO
CTSO
NREF
NREF
Q4 25
-59.5%
216.6%
Q3 25
-33.4%
407.0%
Q2 25
20.2%
184.5%
Q1 25
-16.9%
225.6%
Q4 24
-82.7%
69.9%
Q3 24
-32.1%
186.4%
Q2 24
-48.6%
179.7%
Q1 24
-67.7%
114.3%
EPS (diluted)
CTSO
CTSO
NREF
NREF
Q4 25
$-0.09
$0.47
Q3 25
$-0.05
$1.14
Q2 25
$0.03
$0.54
Q1 25
$-0.02
$0.70
Q4 24
$-0.14
$0.71
Q3 24
$-0.05
$0.74
Q2 24
$-0.08
$0.40
Q1 24
$-0.11
$-0.83

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTSO
CTSO
NREF
NREF
Cash + ST InvestmentsLiquidity on hand
$6.2M
$31.1M
Total DebtLower is stronger
$771.2M
Stockholders' EquityBook value
$5.9M
$388.0M
Total Assets
$44.2M
$5.3B
Debt / EquityLower = less leverage
1.99×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTSO
CTSO
NREF
NREF
Q4 25
$6.2M
$31.1M
Q3 25
$7.5M
$17.9M
Q2 25
$10.2M
$9.1M
Q1 25
$11.6M
$19.2M
Q4 24
$3.3M
$3.9M
Q3 24
$5.7M
$34.7M
Q2 24
$8.5M
$4.3M
Q1 24
$8.6M
$13.5M
Total Debt
CTSO
CTSO
NREF
NREF
Q4 25
$771.2M
Q3 25
$720.9M
Q2 25
$815.6M
Q1 25
$831.5M
Q4 24
$799.3M
Q3 24
$13.8M
$815.5M
Q2 24
$13.7M
$861.0M
Q1 24
$4.4M
$843.3M
Stockholders' Equity
CTSO
CTSO
NREF
NREF
Q4 25
$5.9M
$388.0M
Q3 25
$9.0M
$375.4M
Q2 25
$11.6M
$348.2M
Q1 25
$14.5M
$343.7M
Q4 24
$11.1M
$336.5M
Q3 24
$13.4M
$335.8M
Q2 24
$17.4M
$327.5M
Q1 24
$19.6M
$327.1M
Total Assets
CTSO
CTSO
NREF
NREF
Q4 25
$44.2M
$5.3B
Q3 25
$45.8M
$5.3B
Q2 25
$48.0M
$5.4B
Q1 25
$50.8M
$5.4B
Q4 24
$47.4M
$5.4B
Q3 24
$47.8M
$5.7B
Q2 24
$53.4M
$6.6B
Q1 24
$47.1M
$7.1B
Debt / Equity
CTSO
CTSO
NREF
NREF
Q4 25
1.99×
Q3 25
1.92×
Q2 25
2.34×
Q1 25
2.42×
Q4 24
2.38×
Q3 24
1.03×
2.43×
Q2 24
0.78×
2.63×
Q1 24
0.23×
2.58×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTSO
CTSO
NREF
NREF
Operating Cash FlowLast quarter
$-4.8M
$-4.5M
Free Cash FlowOCF − Capex
$-4.9M
FCF MarginFCF / Revenue
-53.4%
Capex IntensityCapex / Revenue
1.2%
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters
$-12.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTSO
CTSO
NREF
NREF
Q4 25
$-4.8M
$-4.5M
Q3 25
$-2.6M
$8.1M
Q2 25
$-1.5M
$3.3M
Q1 25
$-3.5M
$16.0M
Q4 24
$-2.3M
$4.4M
Q3 24
$-2.5M
$14.7M
Q2 24
$-4.8M
$-7.5M
Q1 24
$-4.8M
$17.7M
Free Cash Flow
CTSO
CTSO
NREF
NREF
Q4 25
$-4.9M
Q3 25
$-2.6M
Q2 25
$-1.5M
Q1 25
$-3.5M
Q4 24
$-2.4M
Q3 24
$-2.6M
Q2 24
$-4.8M
Q1 24
$-4.9M
FCF Margin
CTSO
CTSO
NREF
NREF
Q4 25
-53.4%
Q3 25
-27.3%
Q2 25
-16.1%
Q1 25
-39.7%
Q4 24
-26.3%
Q3 24
-30.4%
Q2 24
-54.4%
Q1 24
-54.2%
Capex Intensity
CTSO
CTSO
NREF
NREF
Q4 25
1.2%
Q3 25
0.2%
Q2 25
0.4%
Q1 25
0.0%
Q4 24
0.8%
Q3 24
1.8%
Q2 24
0.2%
Q1 24
0.5%
Cash Conversion
CTSO
CTSO
NREF
NREF
Q4 25
-0.19×
Q3 25
0.16×
Q2 25
-0.78×
0.15×
Q1 25
0.62×
Q4 24
0.29×
Q3 24
0.63×
Q2 24
-0.62×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTSO
CTSO

Direct$5.1M55%
Distributors And Strategic Partners$4.2M45%

NREF
NREF

Segment breakdown not available.

Related Comparisons